download PDF - Newron
download PDF - Newron
download PDF - Newron
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Key Corporate Events<br />
Completion of the phase III development programme for safinamide as<br />
an add-on therapy for Parkinson’s disease<br />
Agreement signed with Zambon for strategic collaboration and licence<br />
to safinamide covering global rights excluding Japan and key Asian territories<br />
Agreement signed with Meiji Seika for licence to safinamide in Japan and<br />
key Asian territories<br />
New data on safinamide presented as late-breaking news at AAN 2011<br />
Annual Meeting<br />
Approval of IND by the US FDA for NW-3509, a novel compound with<br />
potential as an add-on treatment for patients with schizophrenia<br />
FDA approval of ralfinamide trial in non-responding patients with severe<br />
neuropathic pain of specific causes<br />
Global rights to safinamide regained from Merck Serono<br />
Agreement signed with Merck KGaA to develop two compounds for CNS<br />
diseases